SAINTVILUS ON TECH STOCKS

Regeneron Pharmaceuticals Inc. (REGN)

NASDAQ: Health Care

$135.25

-0.75 | -0.55%

Today's Range: 133.26 - 135.84

REGN Avg. Daily Volume: 847,300

05/30/12 - 10:55 AM ET

TRADE NOW

Insider Trading

Historical Data	Current	1 Mo. Ago	2 Mo. Ago	3 Mo. Ago	4 Mo. Ago	5 Mo. Ago	6 Mo. Ago

Net Insider Transaction	231,117	195,092	15,669	76,556	122,081	149,004	38,383
Shares Bought	1.24M	1.46M	692,689	537,803	626,500	745,746	785,588
Shares Sold	1.01M	1.27M	677,020	461,247	504,419	596,742	747,205

Institutional Trading

Historical Data	Current	1 Mo. Ago	2 Mo. Ago	3 Mo. Ago	4 Mo. Ago	5 Mo. Ago	6 Mo. Ago

Total Shares Held	73.76M	70.56M	71.88M	72.54M	70.53M	70.53M	70.53M
Shares Bought	11.40M	9.09M	9.39M	10.16M	13.75M	13.75M	13.74M
Shares Sold	7.36M	5.97M	5.88M	5.44M	5.65M	5.65M	5.75M

Latest REGN Headlines

More Financial News for REGN

Press Releases for REGN

Sanofi And Regeneron Announce Publication Of Positive Phase 2 Results For Lipid-Lowering PCSK9 Antibody In The Lancet - PR Newswire
Sanofi And Regeneron Announce Regulatory And Clinical Update For ZALTRAPÂ® (aflibercept) - PR Newswire
Sanofi And Regeneron Report Phase 2 Data For Potential First-in-Class Lipid-Lowering PCSK9 Antibody - PR Newswire
Regeneron And Bayer Announce Approval Of EYLEAÂ® (aflibercept) Injection For The Treatment Of Wet Age-Related Macular Degeneration In Australia - PR Newswire
Two Year Results Of Phase 3 Studies With EYLEAâ„¢ (aflibercept) Injection In Wet AMD Show Sustained Improvement In Visual Acuity - PR Newswire
Regeneron And Bayer Initiate Phase 3 Clinical Program For The Treatment Of Wet Age-Related Macular Degeneration In China - PR Newswire
Phase 3 Trial Of ZALTRAPâ„¢ (aflibercept) In Advanced Prostate Cancer To Continue As Planned At Recommendation Of Independent Data Monitoring Committee - PR Newswire
EYLEAâ„¢ (aflibercept Injection) Submitted In Japan For Marketing Authorization For The Treatment Of Wet Age-Related Macular Degeneration - PR Newswire
VEGF Trap-Eye Submitted For EU Marketing Authorization For Treatment Of Wet Age-Related Macular Degeneration - PR Newswire
ZALTRAPâ„¢ (aflibercept) Significantly Improved Survival In Previously Treated Metastatic Colorectal Cancer Patients - PR Newswire

See all press releases.

Refresh Stock Quote for Regeneron Pharmaceuticals Inc. - REGN

TheStreet Premium Services

Compare All Services

Jim Cramer's Action Alerts PLUS:

Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More

OptionsProfits:

Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More

Real Money:

Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More

Stocks Under $10:

Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More

Dow Jones	S&P 500	NASDAQ	10-Year Note
12,424.97	1,314.89	2,830.76	16.47	Oil * 103.33
DOWN 155.72	DOWN 17.53	DOWN 40.23	DOWN 0.84	10 Yr 1.65% SPDR Gold 149.58
-1.24%	-1.32%	-1.40%	-4.85%	Data delayed 20 minutes

Free Newsletters from TheStreet

We respect your privacy.

Manage Newsletters

Podcasts

Daily RSS Updates

TheStreet Mobile Edition

Connect with TheStreet